WELCOME TO The Biotechnology REPORT
Newsletter | Member Login | Signup
Home > Companies > BlueGranite
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Conference
CELL AND GENE THERAPY
Spotlight Therapeutics | December 01, 2020
Spotlight Therapeutics, Inc., a biotechnology organization creating non-viral quality altering therapeutics for direct in vivo altering of target genes, closed its Series A financing bringing the complete raised to $30 million. The financing was driven by GV, in the past Google Ventures, with interest from extra undisclosed investors. Realizing the full revolutionary potential of CRISPR genome editing requires the ability to edit target genes directly in the right cells of the hum...
DIAGNOSTICS
Biodesix | June 06, 2022
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that it intends to develop a new novel minimal residual disease (MRD) test as a part of a master sponsored research agreement (MSRA) with Memorial Sloan Kettering Cancer Center (MSK). In addition, the MSRA between MSK and Biodesix also includes the potential future development of other diagnostic tests aimed at improving the treatment of cancer. Read More
MEDICAL
Mogrify | January 11, 2021
Mogrify Limited (Mogrify®), a UK organization expecting to change the advancement of ex vivo cell therapies and pioneer the field of in vivo reconstructing treatments, and the MRC Laboratory of Molecular Biology (LMB), a top notch research lab committed to understanding significant natural cycles at the sub-atomic level, today reported an exploratory examination cooperation. The venture intends to create novel protein articulation frameworks by utilizing late advances in direct cell reconstr...
INDUSTRIAL IMPACT
Xilio Therapeutics, Inc. | November 28, 2022
Xilio Therapeutics, Inc. a biotechnology company developing tumor-activated immuno-oncology therapies for people living with cancer, announced that the company will host a live virtual program on Thursday, December 1, 2022, at 12:30 p.m. ET spotlighting Xilio’s clinical-stage molecule XTX301, a tumor-activated, engineered IL-12. The event will feature Diwakar Davar, MBBS, M.Sc., a key opinion leader and assistant professor of medicine and a medical oncologist/hematologist fr...
Video
CELL AND GENE THERAPY, MEDTECH
Whitepaper
AI, INDUSTRIAL IMPACT
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE